Literature DB >> 11072898

In vitro activity of the polyether ionophorous antibiotic monensin against the cyst form of Toxoplasma gondii.

S Couzinet1, J F Dubremetz, D Buzoni-Gatel, G Jeminet, G Prensier.   

Abstract

Toxoplasma gondii. The experiments were conducted in vitro using 2 methods; cysts produced either in mice or in cell culture were exposed to monensin in vitro, and the infectivity of the parasites was then assessed in vivo or in vitro. The data obtained from these 2 systems of evaluation showed that monensin inhibits the infectivity and the viability of the bradyzoites. Its activity was time and concentration dependent. The first effects were observed at very low drug concentrations (i.e. 0.0001 microg/ml). Immunofluorescence and electron microscopy analysis showed significant cytological alterations of the monensin-treated bradyzoites: they were swollen, had a large number of vacuoles in their cytoplasm and were found lysed at higher concentrations in ionophore.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072898     DOI: 10.1017/s0031182099006605

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  7 in total

1.  The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1.

Authors:  Mark D Lavine; Gustavo Arrizabalaga
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii.

Authors:  Erin M Garrison; Gustavo Arrizabalaga
Journal:  Mol Microbiol       Date:  2009-03-04       Impact factor: 3.501

3.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

Review 4.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

5.  Boromycin Has Potent Anti-Toxoplasma and Anti-Cryptosporidium Activity.

Authors:  Jaypee Abenoja; Alexis Cotto-Rosario; Roberta O'Connor
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.938

6.  Discovering the Potent Inhibitors Against Babesia bovis in vitro and Babesia microti in vivo by Repurposing the Natural Product Compounds.

Authors:  Yongchang Li; Mohamed Abdo Rizk; Eloiza May Galon; Mingming Liu; Jixu Li; Aaron Edmond Ringo; Shengwei Ji; Iqra Zafar; Maria Agnes Tumwebaze; Byamukama Benedicto; Naoaki Yokoyama; Ikuo Igarashi; Bayin Chahan; Xuenan Xuan
Journal:  Front Vet Sci       Date:  2021-11-29

7.  Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function.

Authors:  Robert A Charvat; Gustavo Arrizabalaga
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.